

2021 HEDIS® Measures

PREVENTIVE SCREENING	
2021 Measure	Quality Indicator
Childhood Immunization <ul style="list-style-type: none"> Children who turn 2 during the measurement year 	Percent of fully immunized 2-year-olds <ul style="list-style-type: none"> 4 DTaP 3 Hep B 3 IVP 2 Influenza 1 MMR 4 Pneumococcal conjugate 3 HIB 2 or 3 Rotavirus 1 Hep A 1 VZV
Adolescent Immunization <ul style="list-style-type: none"> Adolescents who turn 13 during the measurement year 	Percent of fully immunized 13-year-olds <ul style="list-style-type: none"> 1 Meningococcal vaccine between 11 and 13 birthday 1 TD or Tdap on or between 10 and 13 birthday 2 or 3 doses of the HPV vaccine by their 13 birthday For 2 doses, must be administered at least 146 days apart.
Lead Screening <ul style="list-style-type: none"> Children who turn 2 during the measurement year 	Percent with at least one capillary or venous blood test for lead poisoning.
Breast Cancer Screening <ul style="list-style-type: none"> Women age 50-74 	Percent who have had a mammogram during the measurement year or 15 months prior to the measurement year.
Cervical Cancer Screening <ul style="list-style-type: none"> Women age 21-64 	Percent who have had one of the three screenings for cervical cancer such as: <ul style="list-style-type: none"> Woman 21-64 who had a Pap during the measurement year, or the two years prior to the measurement year Women 30-64 who had a Pap and HPV test with the same service dates Woman 30-64 who had a high- risk HPV test during the measurement year or the four years prior to the measurement year.
Colorectal Screening <ul style="list-style-type: none"> Adults age 50-75 	Percent who have had one of five screenings for colorectal cancer such as: <ul style="list-style-type: none"> Fecal occult blood test in the measurement year DNA Fit in the last three years Flexible sigmoidoscopy in the last five years CT colonography in the past five years Colonoscopy in the last 10 years

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

PREVENTIVE SCREENING, continued	
2021 Measure	Quality Indicator
Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents <ul style="list-style-type: none"> Children and adolescents age 3-17 	Percent who have had an outpatient visit with a PCP or OB-GYN during the measurement year with evidence of: <ul style="list-style-type: none"> BMI percentile documentation Counseling for nutrition Counseling for physical activity
Chlamydia Screening <ul style="list-style-type: none"> Women age 16-24 	Percent of sexually active members who have had one test for Chlamydia during the measurement year.

OVERUSE AND APPROPRIATENESS	
2021 Measure	Quality Indicator
Use of Opioids at High Dosage <ul style="list-style-type: none"> Adults age 18 and older 	The rate per 1,000 receiving prescription opioids for ≥ 15 days during the measurement year at a high dosage (average morphine equivalent dose [MME] > 90 mg.)
Use of Opioids from Multiple Providers <ul style="list-style-type: none"> Adults age 18 and older 	The rate per 1,000 receiving prescription opioids for ≥ 15 days during the measurement year who received opioids from multiple providers
Risk of Continued Opioid Use <ul style="list-style-type: none"> Adults Age 18 and older 	The percentage of members who have a new episode of opioid use that puts them at risk for continued opioid use. Two rates are reported: <ul style="list-style-type: none"> At least 15 days of prescription opioids in a 30-day period At least 31 days of prescription opioids in a 62-day period
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS) <ul style="list-style-type: none"> Adolescent females 16-20 years of age 	Adolescent females 16-20 years of age who were screened unnecessarily for cervical cancer.
Appropriate Treatment for URI <ul style="list-style-type: none"> Members age 3 months and older 	Percent of members with a diagnosis of URI who were NOT dispensed an antibiotic.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

OVERUSE AND APPROPRIATENESS, CONTINUED	
2021 Measure	Quality Indicator
Use of Imaging Studies for Low Back Pain <ul style="list-style-type: none"> Adults age 18-50 	Percent of members with a primary diagnosis of low back pain, who have had NO imaging in the 28 days following the initial diagnosis.
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis <ul style="list-style-type: none"> Members age 3 months and older 	Percent of members with a diagnosis of acute bronchitis who were NOT dispensed an antibiotic.

UTILIZATION	
2021 Measure	Quality Indicator
Well-Child Visits <ul style="list-style-type: none"> First 30 months of life 	The percentage of members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported: <ul style="list-style-type: none"> Children who turned 15 months old during the measurement year: Six or more well-child visits Children who turned 30 months old during the measurement year: Two or more well-child visits
Child and Adolescent Well-Care Visits <ul style="list-style-type: none"> Patients age 3-21 	Percent of members who have had at least one comprehensive well visit with a PCP or OB-GYN practitioner during the measurement year.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

BEHAVIORAL HEALTH	
2021 Measure	Quality Indicator
<p>Antidepressant Medication Management</p> <ul style="list-style-type: none"> Adults age 18 and older 	<p>Percent of members who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported:</p> <ul style="list-style-type: none"> Acute Phase: members who remained on an antidepressant for at least 84 days Continuation Phase: The percentage of members who remained on an antidepressant medication for at least 180 days
<p>Follow-up Care for Children Prescribed ADHD Medication</p> <ul style="list-style-type: none"> Members age 6-12 	<p>Percent of children newly prescribed ADHD medication who had follow up visits within a 10-month period. Two rates are reported:</p> <ul style="list-style-type: none"> Initiation Phase: One follow up visit within 30 days of the start of the medication Continuation and Maintenance Phase: Two additional follow up visits in addition to the initiation visit within 31-300 days after the start of a medication
<p>Follow-up After Hospitalization for Mental Illness</p> <ul style="list-style-type: none"> Members 6 and older 	<p>Percent of discharges for members who were hospitalized for treatment of selected mental health disorders that within 7 days of discharge, and within 30 days of discharge, had one of the following with a mental health provider:</p> <ul style="list-style-type: none"> An outpatient visit An intensive outpatient encounter, or A partial hospitalization A community mental health center visit Electroconvulsive therapy A telehealth visit An observation visit Transitional care management services

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

BEHAVIORAL HEALTH, continued	
2021 Measure	Quality Indicator
Diabetes Monitoring for People with Diabetes and Schizophrenia <ul style="list-style-type: none"> Adults age 18-64 	Percent of members with schizophrenia and diabetes who had both LDL-C and HbA1c test during the measurement year.
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia <ul style="list-style-type: none"> Adults age 18-64 	Percent of members with schizophrenia and cardiovascular disease, who had an LDL-C testing during the measurement year.
Follow up After High Intensity Care for Substance Use Disorder <ul style="list-style-type: none"> Members age 13 and older 	Percent of members who had an inpatient, residential treatment or detoxification visit for a diagnosis of substance use disorder who had a follow up visit for substance use disorder: <ul style="list-style-type: none"> Follow up visit within 7 days after discharge or visit Follow up visit within 30 days after discharge or visit
Adherence to Antipsychotic Medications for Individuals with Schizophrenia <ul style="list-style-type: none"> Adults 18 and older 	Percent of members diagnosed with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80% of the treatment period.
Pharmacotherapy for Opioid Use Disorder <ul style="list-style-type: none"> Members age 16 and older 	Percent of new opioid use disorder pharmacotherapy events for 180 or more days for members with a diagnosis of OUD. <ul style="list-style-type: none"> No gaps in treatment of 8 or more consecutive calendar days
Metabolic Monitoring for Children and Adolescents on Antipsychotics <ul style="list-style-type: none"> Members age 1-17 	Percent of children and adolescents who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported: <ul style="list-style-type: none"> Received blood glucose testing Received cholesterol testing Received blood glucose and cholesterol testing

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

BEHAVIORAL HEALTH, continued	
2021 Measure	Quality Indicator
Follow-up After Emergency Department Visit for Mental Illness <ul style="list-style-type: none"> Members 6 and older 	Percent of members with emergency department visits with a principal diagnosis of mental illness who had a follow up visit for mental illness: <ul style="list-style-type: none"> Follow up visit within 7 days of ED visit Follow up visit within 30 days of ED visit
Follow-up After Emergency Department Visit for Alcohol or Other Drug Abuse or Dependence <ul style="list-style-type: none"> Members 13 and older 	Percent of members with emergency department visits with a principal diagnosis of alcohol or other drug abuse or dependence (AOD) who had a follow up visit for AOD: <ul style="list-style-type: none"> Follow up visit within 7 days of ED visit Follow up visit within 30 days of ED visit
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who are Using Antipsychotics <ul style="list-style-type: none"> Adults age 18-64 	Percent of members with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test (glucose or HbA1c) during the measurement year.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

RESPIRATORY CONDITIONS	
2021 Measure	Quality Indicator
Appropriate Testing for Pharyngitis <ul style="list-style-type: none"> Members age 3 and older 	Percent of members with a diagnosis of pharyngitis who were dispensed an antibiotic and received a strep test for the episode of care.
Use of Spirometry Testing in the Assessment and Diagnosis of COPD <ul style="list-style-type: none"> Adults 40 and older 	Percent of members with a new diagnosis of COPD who received a spirometry to confirm diagnosis.
Pharmacotherapy Management of COPD Exacerbation <ul style="list-style-type: none"> Adults over 39 	The percent of COPD exacerbations for members who had an acute inpatient discharge or ED visit on or between Jan. 1- Nov. 30 of the measurement year, who were dispensed appropriate medications. Two rates are reported: <ul style="list-style-type: none"> Dispensed a systemic corticosteroid (or evidence of an active prescription) within 14 days of the event Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event
Asthma Medication Ratio <ul style="list-style-type: none"> Age 5-64 	Percent of members who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

CARDIOVASCULAR	
2021 Measure	Quality Indicator
Controlling High Blood Pressure <ul style="list-style-type: none"> Adults age 18-85 	Percent of members: <ul style="list-style-type: none"> With a diagnosis of hypertension, have a blood pressure of < 140/90 during the measurement year.
Persistence of a Beta-Blocker After a Heart Attack <ul style="list-style-type: none"> Adults age 18 and up 	Percent of members who were hospitalized with an acute myocardial infarction who received a persistent beta blocker for six months after discharge.
Statin Therapy for Patients with Cardiovascular Disease <ul style="list-style-type: none"> Men 21-75 Women 40-75 	Percent of members who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) who were dispensed a high or moderate-intensity statin medication. Two rates are reported: <ul style="list-style-type: none"> Received statin therapy; dispensed at least one medication during the measurement year Statin adherence 80%; remained on medication for at least 80% of the treatment period.
Cardiac Rehabilitation <ul style="list-style-type: none"> Adults age 18 and older 	The percentage of members who attend cardiac rehabilitation following a qualifying cardiac event. Four rates are reported: <ul style="list-style-type: none"> Initiation: attended 2 or more sessions within 30 days after a qualifying event Engagement 1: attended 12 or more sessions within 90 days after a qualifying event Engagement 2: attended 24 or more sessions within 180 days after a qualifying event Achievement: attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

ACCESS AND AVAILABILITY OF CARE	
2021 Measure	Quality Indicator
Adult Access to Preventive/Ambulatory Health Services <ul style="list-style-type: none"> Adults age 20 and older 	<p>Percent of Medicaid members who have had one or more ambulatory or preventive visit during the measurement year.</p> <p>Percent of Commercial members who have had one or more ambulatory or preventive visits during the measurement year, or the two years prior to the measurement year.</p>
Prenatal and Postpartum Care	<p>Percent of members who:</p> <ul style="list-style-type: none"> Received care within their first trimester, or within 42 days of enrollment Received a postpartum visit between 7 and 84 days after delivery
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment <ul style="list-style-type: none"> Adolescent and adult members age 13 and older 	<p>Percent of members with a new episode of alcohol or other drug abuse or dependence who received the following:</p> <ul style="list-style-type: none"> Initiation – Initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth or medication treatment within 14 days of the diagnosis Engagement – Initiated treatment and who were engaged in ongoing AOD treatment within 34 days of the initiation visit
Use of First Line Psychosocial Care for Children and Adolescents on Antipsychotics <ul style="list-style-type: none"> Children and adolescents age 1-17 	<ul style="list-style-type: none"> Percent of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

2021 HEDIS® Measures

DIABETES	
Comprehensive Diabetes Care (18-75)	
2021 Measure	Quality Indicator
HbA1c Testing	Percent of members with one HbA1c test during the measurement year.
HbA1c Poor Control <ul style="list-style-type: none"> • >9% 	Percent of members with HbA1c result higher than 9.0.
HbA1c Good Control <ul style="list-style-type: none"> • < 8% 	Percent of members with HbA1c result lower than 8.0.
Eye Exam <ul style="list-style-type: none"> • Retinal 	Percent of members who have had an annual retinal exam in the measurement year or have had a negative exam in the year prior.
Blood Pressure Control <ul style="list-style-type: none"> • <140/90 mm Hg 	Percent of members with acceptable BP <140/90 mm Hg.
Statin Therapy for Patients with Diabetes <ul style="list-style-type: none"> • Members age 40-75 	Percent of members with diabetes who were identified as not having clinical atherosclerotic cardiovascular disease (ASCVD). Two rates reported: <ul style="list-style-type: none"> • Received statin therapy; dispensed at least one medication during the measurement year • Statin adherence 80%; remained on medication for at least 80% of the treatment period
Kidney Health Evaluation for Patients With Diabetes <ul style="list-style-type: none"> • Members age 18-85 	Percentage of members with diabetes who received a kidney health evaluation, defined by an estimated glomerular filtration rate and a urine albumin creatinine ration, during the measurement year.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

G-3245 Beecher Road • Flint, Michigan • 48532

tel 888-327-0671 • fax 833-540-8648

McLarenHealthPlan.org

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
G-3245 Beecher Road • Flint, Michigan • 48532
tel 888-327-0671 • fax 833-540-8648
McLarenHealthPlan.org